DURECT Corporation (NASDAQ: DRRX) has announced its financial results for the first quarter of 2024, revealing a decline in total revenue compared to the same period last year.
The company reported a decrease in revenue primarily due to lower sales from feasibility agreements and product sales. However, DURECT highlighted a significant reduction in both research and development (R&D) and selling, general, and administrative (SG&A) expenses.
The company believes its current cash reserves are sufficient to fund operations through the end of 2024. During the call, DURECT also provided an update on the progress of its lead product candidate, larsucosterol, for the treatment of alcohol-associated hepatitis (AH), indicating a potential path towards a New Drug Application (NDA) with the FDA based on a successful Phase III trial.
Key Takeaways
- Total revenue for Q1 2024 was $1.8 million, down from $2.1 million in Q1 2023.
- R&D expenses decreased to $4.1 million, down from $8.6 million in the previous year.
- SG&A expenses also fell to $3.1 million from $4.1 million in the prior year.
- Cash and investments totaled $21.6 million as of March 31, 2024.
- The company's cash burn for Q1 was $8.9 million, excluding approximately $650,000 from ATM financing.
- DURECT is preparing for a Phase III trial of larsucosterol in AH, with potential for an NDA filing based on a single successful Phase III trial.
Company Outlook
- DURECT anticipates sufficient cash to support operations through the end of 2024.
- The company is focusing on the development of larsucosterol for AH, with a pivotal Phase III trial in the works.
Bearish Highlights
- Revenue decreased due to lower sales from feasibility agreements and product sales.
Bullish Highlights
- Significant reductions in R&D and SG&A expenses.
- Potential for larsucosterol to be the first FDA-approved treatment for AH.
- Larsucosterol has shown a strong safety profile and a clinically meaningful survival benefit in AH patients.
Misses
- Neither the primary nor key secondary endpoint results in the AHFIRM Phase IIb trial achieved statistical significance.
Q&A Highlights
- Additional data from the AHFIRM trial will be presented at the EASL conference in June and possibly at the AASLD meeting in the fall.
- The focus for larsucosterol remains on severe AH patients, with a MELD score of 21 to 30, though there is potential for future application in moderate AH patients.
- The design and initiation timeline for the Phase III trial are being finalized, with details to be disclosed later in the year.
- Financing options for the Phase III trial are being explored, including business development and financial markets.
DURECT Corporation's Q1 2024 earnings call highlighted the company's efforts to advance larsucosterol, despite a decrease in revenue.
With a strong focus on the development and potential approval of larsucosterol for AH, DURECT is poised to potentially establish a new standard of care for this severe condition.
The upcoming Phase III trial and presentations at medical conferences are key milestones that the medical and investment communities are anticipating.
InvestingPro Insights
DURECT Corporation (NASDAQ: DRRX) faces a challenging market environment, as reflected in its financial results for Q1 2024. Despite a decrease in total revenue, the company's management remains optimistic about its lead product candidate, larsucosterol. To provide a comprehensive view of DURECT's financial health and market performance, InvestingPro offers the following insights:
InvestingPro Tips:
- DURECT holds more cash than debt on its balance sheet, which could provide some financial stability as the company progresses towards its Phase III trial for larsucosterol.
- Two analysts have revised their earnings upwards for the upcoming period, suggesting a potential improvement in the company's financial outlook.
InvestingPro Data:
- The market capitalization of DURECT stands at $33.21 million, reflecting the market's current valuation of the company.
- The P/E Ratio (Adjusted) for the last twelve months as of Q4 2023 is -1.2, indicating that the company is not currently profitable.
- DURECT's revenue has decreased by 55.67% over the last twelve months as of Q4 2023, highlighting the challenges faced in generating sales.
DURECT Corporation's strategic focus on reducing R&D and SG&A expenses could be a prudent move in light of the current financial data. While the company navigates through its cash reserves, the upward earnings revision by analysts and the cash position relative to debt may provide some optimism for investors.
For those seeking more detailed analysis and additional InvestingPro Tips, visit https://www.investing.com/pro/DRRX. There are 11 more tips available on InvestingPro that could help investors make informed decisions about DURECT Corporation. To access these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
Full transcript - Durect Corp (NASDAQ:DRRX) Q1 2024:
Operator: Greetings, and welcome to the DURECT Corporation First Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Tim Papp, Chief Financial Officer. Thank you, sir. You may begin.
Timothy M. Papp: Good afternoon, and welcome to DURECT Corporation's First Quarter 2024 Earnings Conference Call. This is Tim Papp, Chief Financial Officer of DURECT. Before we begin, I would like to remind you of our Safe Harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT products in development, expected product benefits, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings, including our 10-K and 10-Qs under the heading Risk Factors. To begin, I’d like to review our first quarter 2024 financial results. Total revenues in the first quarter of 2024 were $1.8 million compared to $2.1 million in 2023. 2024 revenues were lower primarily due to lower revenues from feasibility agreements, as well as lower revenue from product sales. R&D expense was $4.1 million in the first quarter of 2024 compared to $8.6 million for the prior year. The decrease was primarily due to lower clinical trial-related expenses as we substantially completed the AHFIRM trial and lower employee related costs. SG&A expenses were $3.1 million in the first quarter of 2024 compared to $4.1 million for the prior year. The decrease was primarily due to lower market research expenses, lower patent expenses, as well as lower employee costs. As of March 31, 2024 we had cash and investments of $21.6 million as compared to $29.8 million at December 31, 2023 and our cash burn for the first quarter was $8.9 million, excluding net proceeds of approximately $650,000 from ATM financing. We believe our cash on hand is sufficient to fund operations through the end of 2024. Now I would like to turn the call over to Jim for a business update.
James E. Brown: Thank you, Tim. Hello, everyone and thank you for joining us today. We are making good progress towards initiating our Phase III clinical trial for larsucosterol in alcohol-associated hepatitis. Through a Type C meeting with the FDA, we have received feedback that a single Phase III trial, if successful could be sufficient to support an NDA filing in AH. We are in the process of designing a pivotal trial that incorporates the FDA feedback and the key learnings from our AHFIRM Phase IIb trial. We are continuing to analyze the clinical data from AHFIRM and believe the data provide a strong foundation for the design of our registrational Phase III trial. We look forward to sharing additional data analyses and the details of the protocol in an update later this year. We are also excited that the AHFIRM data has been accepted for an oral, late-breaker presentation at the upcoming EASL conference in June of this year. This will be our first opportunity to share the AHFIRM data with the medical community at a scientific meeting. We are very encouraged by the continued enthusiasm of the hepatology thought leaders and key opinion leaders for the AHFIRM results and their recognition of larsucosterol's potential to provide a clinically meaningful survival benefit in AH patients. As a brief reminder, AHFIRM was a placebo-controlled, double-blind multinational study with two active arms of 30 milligrams and 90 milligrams of larsucosterol and a placebo arm of approximately 100 patients each. In total, we randomized 307 patients with severe AH, from a global network of clinical sites. Our sites included renowned liver centers in the United States, Australia, the EU and the UK. We had the honor of working with some of the world's preeminent thought leaders in AH. The top-line results and the key secondary endpoint of mortality at 90 days showed a 41% reduction with the 30 milligram dose of larsucosterol and a 35% reduction with the 90-milligram dose of larsucosterol as compared with placebo. We also reported a numerical improvement in the primary endpoint of reduction in mortality or liver transplant at 90 days, though neither the primary or key secondary endpoint results achieved statistical significance. Even more impressive results were observed in the US population, which comprised three-quarters of the total enrollment in AHFIRM and that was 232 out of the 307 patients. In the U.S. patients, we saw reductions in the 90-day mortality of 57% and 58% for the 30 milligram and 90-milligram arms respectively, as compared with placebo. Although not part of the original statistical analysis plan, the p-values for these results were both approximately 0.01. Very importantly, larsucosterol exhibited an excellent safety profile with no serious adverse events in either arm and greater than 20% reductions in the number of treatment-emergent adverse events for both active arms in these severely ill patients. Ultimately, these clinically meaningful reductions in mortality coupled with the reduction in adverse events in these severely ill patients reinforce the compelling risk-reward proposition for larsucosterol. We continue to believe that the AHFIRM data provide compelling evidence that larsucosterol could represent a safe and effective therapy with life-saving potential for AH patients. There are no approved therapies for AH today. So if larsucosterol meets our expectation in the Phase III, and we are able to gain approval, it would likely be the first FDA-approved treatment for this disease and establish a new standard of care. AH is the cause of more than 160,000 hospitalizations each year in the United States and with a 90 day mortality rate of approximately 30% is responsible for tens of thousands of deaths each year. In addition to its high mortality rate, AH represents a significant cost to the US health care system. Hospitalizations attributed to AH incur charges between $67,000 to $180,000 per patient, a total charge to hospitals of approximately $10 billion annually. As a result larsucosterol represents a potential blockbuster opportunity in the US alone and could simultaneously provide overall cost savings to the health care system. We would now like to take any questions you may have.
Operator: Thank you. We will now be conducting a question-and-answer session. [Operator Instructions] Our first question comes from Frank Brisebois with Oppenheimer & Co. Please proceed with your question.
Francois Brisebois: Hi, thanks for the question. I was just wondering if you can share anything around EASL late break? Is there -- should we be expecting new data? Or can you share anything about kind of progress with the FDA? Or just any thoughts on EASL would be helpful. Thank you.
James E. Brown: Yes. Sure, Frank. First of all, good to catch up. Yes. The-late breaker is the first time we'll have an opportunity to present the data from AHFIRM. And so we'll be focusing on a lot of what's understood today. We won't be giving additional FDA updates beyond what we just talked about at this call. But it certainly is quite an honor to receive an oral late-breaker opportunity here and to present the data. They're very important data. And as well, I believe we should be presenting some additional data this fall at the AASLD meeting, as we continue to learn more and more about the results from this trial.
Francois Brisebois: Okay. That's helpful. And then in terms of the patient severity based on MELD scores. Is there -- I know there is moderate-to-severe was kind of a thought. Has there ever been a thought of the milder patient population? Or is that patient population not necessarily going to the hospital? Just any thoughts about the milder additionally.
James E. Brown: Yes. Yes, we certainly -- we look at all, and I believe this drug will have an opportunity to help all. We certainly saw that tendency in the Phase IIa. It is a smaller trial, but we treated both moderate and severe patients in that. But our focus right now has been on the severe patients, patients with a MELD score of 21 to 30. Put that in perspective, you have a MELD of 21 that means you got about 20% chance of dying in the next 90 days. And if it's -- MELD is 30, you have about a 60% chance of dying. So they are very ill. That being said, moderates still have 7% to 10% to 15% to 20% chance of dying. So they're not -- they're in a dangerous position as well. So a lot of the patients in the hospital are "moderate" patients. But with the objective here and the ultimate goal is to get this product approved with the opportunity to hopefully save lives. That's what we're focusing on with this molecule. And we think the fastest way to do that is to stay in the severe patient population where it's easier to distinguish a benefit of the drug, which we certainly saw in the U.S. data and now with further analysis, we're seeing information that helps really understand things globally as well. So all that being said, we feel very good about where we are going with the severes. I think eventually, if the product is approved for severe, we will roll it out for use in moderates as well with additional studies.
Francois Brisebois: Thank you.
Operator: Our next question comes from Carl Byrnes with Northland Capital Markets. Please proceed with your question.
Carl Byrnes: Thanks for the question. Understanding that you're yet to define the pivotal study in terms of the trial design, do you have any target in terms of initiation date internally or anything that you can disclose at this juncture?
James E. Brown: Yes. We'll be breaking that out as the year unfolds, but we are working on the protocol right now. The hope would be to start it -- get it underway as soon as we possibly can. So I mean that's – there is every month that goes by, more patients are at risk of dying from this disease. And so we're doing everything we can to get the opportunity lined up from a business perspective to be able to do that. And so that's our entire focus.
Carl Byrnes: Great. Thanks.
Operator: Our next question comes from Ed Arce with H.C. Wainwright. Please proceed with your question.
Thomas Yip: Hi, good afternoon everyone. This is Thomas Yip asking a couple of questions for Ed. Thank you very much for the opportunity. So first, can you discuss some preliminary thoughts on the trial design, key elements of the Phase III study especially efficacy end point and perhaps any parallels or contrast between the Phase III study and the Phase II study?
James E. Brown: We absolutely look forward to doing that. We are not going to do it right now because we're still finalizing that protocol. But once we are, we'll light it out and we are doing it with the learnings that have come from AHFIRM. So we will be able to, I think, quite logically lay out. What we're looking at the number of patients, the way the trial will be designed and administered. There certainly are some key lessons learned from AHFIRM that I think will help make this a very efficient trial and with an opportunity to amplify the potential efficacy and as I said, get this thing going and get it on the market as soon as we can.
Thomas Yip: Understood. And then perhaps the other key elements with the Phase III study perhaps is the way to finance this study. Can you discuss what are some options and, perhaps, the timing of any such decisions to move into phase III.
James E. Brown: Yes. We certainly have a number of options in front of us. And there is a large effort that, that Tim is undertaking. So perhaps, Tim, maybe I'll let you jump in on that one.
Timothy M. Papp: Yes, absolutely. I don't think we're doing anything that is unexpected at this point. We obviously will need additional financing to complete the Phase III and that can come from a variety of sources, as Jim referred to, whether it's business development or the financial markets. So we can't give you any specifics on the details at this point around timing or what that might look like. But rest assured – we are undertaking the appropriate processes to find that financing.
Thomas Yip: Thank you for taking the questions. We'll look forward to the EASL presentation and then with the Phase III trial design later this year.
Timothy M. Papp: Absolutely thank you.
Operator: It appears that there are no further questions at this time. I would now like to turn the floor back over to Jim Brown for closing comments.
James E. Brown: Yes. With that, I just want to thank you all for your attention and your time. And as always please feel free to reach out. We look forward to catching up with all of you. Take care. Bye.
Operator: This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.